BIOCERES CROP SOLUTIONS CORP
BIOXNASDAQTrading Snapshot
- Day Range
- $0.19 β $0.20
- 52-Week Range
- $0.16 β $1.73
- Volume (shares)
- 804
- Avg Volume (shares)
- β
- Shares Outstanding
- 63.8M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $238M
- Last Q Revenue
- $57M
- P/E Ratio
- β
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-4.06
- Dividend Yield
- β
- Dilution (1yr)
- +0.2%
BIOCERES CROP SOLUTIONS CORP
BIOXAbout BIOCERES CROP SOLUTIONS CORP
Bioceres Crop Solutions Corp. (BIOX) is a company dedicated to enhancing agricultural output through a diverse range of solutions. Its operations are organized into three principal divisions. The Seed and Integrated Products segment is responsible for creating and bringing to market cutting-edge seed technologies, genetic material, biotechnological innovations, and specialized seed coatings. Under its Crop Protection segment, the company formulates, manufactures, and distributes a comprehensive array of products, including Rizoderma, various adjuvants, therapeutic agents, weed killers, insect eradicators, fungal treatments, and pest lures. The Crop Nutrition unit focuses on the development, production, and distribution of inoculants, bio-stimulants, and both organic and micro-granular fertilizers. A notable offering from Bioceres is HB4, an innovative seed technology engineered for drought resistance. The enterprise maintains a significant presence across several countries, including Argentina, Uruguay, France, and South Africa, alongside broader international operations. Established in 2001, the firm's main offices are situated in Rosario, Argentina. Bioceres Crop Solutions Corp. functions as a subsidiary entity under the umbrella of Bioceres LLC.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates
News unavailable.